Development of cancer peptide vaccine therapy against newly target gene for invasive intraductal papillary mucinous carcinoma

2015 Fiscal Year Final Research Report

• Project/Area Number: 26861096
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Digestive surgery
• Research Institution: Wakayama Medical University
• Principal Investigator: SHIMIZU Atsushi 和歌山県立医科大学, 医学部, その他 (00637910)
• Project Period (FY): 2014-04-01 – 2016-03-31
• Keywords: MUC16 / mesothelin / IPMN / ペプチドワクチン療法

Outline of Final Research Achievements

MUC16 and mesothelin has been hopeful as a newly target gene for pancreatic ductal adenocarcinoma. In this studty, we investigated the clinicopathological and molecular biological function of　MUC16 and mesothelin for the intraductal papillary mucinous neoplasm (IPMN) to develop the cancer peptide vaccine therapy. In the result, MUC16/mesothelin were not expressed in the low-, intermediate, and high- grade dysplasia, but expressed invasive IPMC. However, MUC16/mesothelin high expression was not an independent prognostic factor for overall survival. We cultured the cell line of IPMC derived from surgical specimens and performed the expression and co-expression analyses of MUC16/mesothelin.

Free Research Field

膵臓外科学